logo

Kintara Therapeutics, Inc (KTRA)



Trade KTRA now with
  Date
  Headline
5/27/2022 10:10:13 AM Kintara Reports First European Site Activation In GCAR Phase 2/3 Trial For Glioblastoma
2/11/2022 8:26:48 AM Kintara Therapeutics Q2 Loss/shr $0.12 Vs. Loss/shr $0.22 Prior Year
2/11/2022 8:26:02 AM Kintara Therapeutics Q2 Loss/shr $0.12 Vs. Loss/shr $0.22 Prior Year
11/18/2021 8:10:42 AM Kintara Presents Updates On Two Phase 2 Clinical Studies On Neuro-oncology
9/29/2021 8:10:52 AM Kintara Therapeutics FY Loss Per Share $1.60 Vs Loss $0.87 Last Year
6/3/2021 8:02:45 AM Kintara Therapeutics Says Enrolls Final Patient In Phase 2 Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors
5/26/2021 8:14:28 AM Kintara Therapeutics Provides Positive Site Activation Update On GCAR Phase 2/3 Clinical Trial For Glioblastoma
5/14/2021 8:35:39 AM Amended: Kintara Therapeutics Q3 Loss Per Share $0.23 Vs Loss Per Share $0.17 Last Year
5/4/2021 8:27:54 AM Kintara Therapeutics Appoints Tamara Seymour To Board
4/12/2021 8:23:44 AM Kintara Presents Interim Data Results On Two Phase 2 Clinical Trials Of VAL-083 At AACR Annual Meeting